Prevention, diagnosis, therapy and aftercare of sepsis: The first revision of the S2k guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI);Prävention, diagnose, therapie und nachsorge der sepsis: 1. Revision der S2k-leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI)

Intensiv- und Notfallbehandlung

Volumn 35, Issue 2, 2010, Pages 56-104

  Reinhart, K ^a   Brunkhorst, F M ^a   Bone, H G ^b   Bardutzky, J ^c   Dempfle, C E ^d   Forst, H ^e   Gastmeier, P ^f   Gerlach, H ^g   Grundling M ^h   John, S ⁱ   Kern, W ^j   Kreymann, G ^k   Kruger W ^l   Kujath, P ^m   Marggraf, G ⁿ   Martin, J ^o   Mayer, K ^p   Meier Hellmann, A ^q   Oppert, M ^f   Putensen, C ^r   Quintel, M ^s   Ragaller, M ^t   Rossaint, R ^u   Seifert, H ^v   Spies, C ^f   Stuber F ^w   Weiler, N ^m   Weimann, A ^x   Werdan, K ^y   Welte, T ^z   more..

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Knappschaftskrankenhaus Recklinghausen   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e KLINIKUM AUGSBURG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^h UNIVERSITY OF GREIFSWALD   (Germany)

ⁱ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^j UNIVERSITY OF FREIBURG   (Germany)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l KLINIKUM KONSTANZ   (Germany)

^m UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁿ UNIVERSITY HOSPITAL ESSEN   (Germany)

^o KLINIK AM EICHERT   (Germany)

^p JUSTUS LIEBIG UNIVERSITY   (Germany)

^q HELIOS KLINIKUM ERFURT   (Germany)

^r UNIVERSITY OF BONN   (Germany)

^s UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^t UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^u RWTH AACHEN UNIVERSITY   (Germany)

^v UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^w UNIVERSITY OF BERN   (Switzerland)

^x Klinikum St Georg   (Germany)

^y MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^z HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

Aftercare; Diagnosis; Prevention; Sepsis; Therapy

Indexed keywords

REVIEW; SEPSIS;

EID: 77957832879     PISSN: 09475362     EISSN: None     Source Type: Journal    
DOI: 10.5414/ibp35056     Document Type: Review

References (409)

1. Yusuf S, Teo K, Woods K. Intravenous magnesium in acute myocardial infarction. An effective, safe, simple, and inexpensive intervention. Circulation. 1993; 87: 2043-2046.
2. ISIS-4. Arandomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995; 345: 669-685.
3. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989; 95 (Suppl 2): 2S-4S.
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348: 1546-1554.
5. Bates DW, Cook EF, Goldman L, Lee TH. Predicting bacteremia in hospitalized patients. Aprospectively validated model. Ann Intern Med. 1990; 113: 495-500.
6. Bates DW, Sands K, Miller E, Lanken PN, Hibberd PL, Graman PS et al. Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group. J Infect Dis. 1997; 176: 1538-1551.
7. Crowe M, Ispahani P, Humphreys H, Kelley T, Winter R. Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985 - 1996. Eur J Clin Microbiol Infect Dis. 1998; 17: 377-384.
8. Leibovici L, Greenshtain S, Cohen O, Mor F, Wysenbeek AJ. Bacteremia in febrile patients. A clinical model for diagnosis. Arch Intern Med. 1991; 151: 1801-1806.
9. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995; 274: 639-644.
10. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002; 28: 108-121. (Pubitemid 34293822)
11. ACCP/SCCM Consensus Conference Committee. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20: 864-874.
12. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. In: Olmsted RN (ed). PIC infection control and applied epidemiology: principles and practice. St. Louis: Mosby; 1996, A1-A20.
13. Clec'h C, FerriereF, Karoubi P, Fosse JP, Cupa M, Hoang P et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med. 2004; 32: 1166-1169.
14. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001; 164: 396-402. (Pubitemid 32778205)
15. Müller B, Becker KL, Schächinger H, Rickenbacher PR, Huber PR, Zimmerli W et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000; 28: 977-983. (Pubitemid 30262065)
16. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med. 2000; 26 (Suppl 2): S148-S152.
17. Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schuttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med. 1998; 24: 680-684. (Pubitemid 28393399)
18. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008; 177: 498-505. (Pubitemid 351442188)
19. Gramm HJ, Hannemann L, Reinhart K, Lode H. Sepsis: Ein Begriff imWandel. Möglichkeiten und Grenzen der Diagnose anhand klinischer Kriterien. Dtsch MedWochenschr. 1995; 120: 498-502.
20. Smith-Elekes S, Weinstein MP. Blood cultures. Infect Dis Clin North Am. 1993; 7: 221-234.
21. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994; 79: 1605-1608.
22. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev. 1997; 10: 444-465.
23. Dellinger RP, Carlet J, Masur H, Gerlach H, Calandra T, Cohen J et al. Surviving Sepsis Campaign for management of severe sepsis and septic shock. Crit Care Med. 2004; 32: 858-872. (Pubitemid 38344143)
24. Shafazand S, Weinacker AB. Blood cultures in the critical care unit: improving utilization and yield. Chest. 2002; 122: 1727-1736. (Pubitemid 35366089)
25. Darby JM, Linden P, Pasculle W, Saul M. Utilization and diagnostic yield of blood cultures in a surgical intensive care unit. Crit Care Med. 1997; 25: 989-994. (Pubitemid 27264244)
26. Shahar E,Wohl-Gottesman BS, Shenkman L. Contamination of blood cultures during venepuncture: fact or myth? Postgrad Med J. 1990; 66: 1053-1058.
27. Souvenir D, Anderson DE Jr, Palpant S, Mroch H, Askin S, Anderson J et al. Blood cultures positive for coagulase-negative staphylococci: antisepsis, pseudobacteremia, and therapy of patients. J Clin Microbiol. 1998; 36: 1923-1926. (Pubitemid 28277777)
28. Martinez JA, DesJardin JA, Aronoff M, Supran S, Nasraway SA, Snydman DR. Clinical utility of blood cultures drawn from central venous or arterial catheters in critically ill surgical patients. Crit Care Med. 2002; 30: 7-13. (Pubitemid 34112170)
29. Wilson ML. General principles of specimen collection and transport. Clin Infect Dis. 1996; 22: 766-777.
30. Spitalnic SJ, Woolard RH, Mermel LA. The significance of changing needles when inoculating blood cultures: a meta-analysis. Clin Infect Dis. 1995; 21: 1103-1106.
31. Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997; 24: 584-602. (Pubitemid 27143552)
32. Washington JA 2nd. Blood cultures: principles and techniques. Mayo Clin Proc. 1975; 50: 91-98.
33. Li J, Plorde JJ, Carlson LG. Effects of volume and periodicity on blood cultures. J Clin Microbiol. 1994; 32: 2829-2831. (Pubitemid 24319127)
34. Seifert HMA-HGF, Glück T, Jansen B, Kern WV et al. MiQ 3a: Blutkulturdiagnostik Sepsis, Endokarditis, Katheterinfektionen, Teil I. München: Urban & Fischer; 2007.
35. Bloos F, Hinder F, Becker K, Sachse S, Mekontso Dessap A, Straube E et al. A multicenter trial to compare blood culture with polymerase chain reaction in severe human sepsis. Intensive Care Med. 2010; 36: 241-247.
36. Lehmann LE, Alvarez J, Hunfeld KP, Goglio A, Kost GJ, Louie RF et al. Potential clinical utility of polymerase chain reaction in microbiological testing for sepsis. Crit Care Med. 2009; 37: 3085-3090.
37. Louie RF, Tang Z, Albertson TE, Cohen S, Tran NK, Kost GJ. Multiplex polymerase chain reaction detection enhancement of bacteremia and fungemia. Crit Care Med. 2008; 36: 1487-1492. (Pubitemid 351620647)
38. Schrenzel J. Clinical relevance of new diagnostic methods for bloodstream infections. Int J Antimicrob Agents. 2007; 30 (Suppl 1): S2-6.
39. American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator- associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171: 388-416.
40. Hoffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K et al. S3-Guideline on ambulant acquired pneumonia and deep airway infections. Pneumologie. 2005; 59: 612-664.
41. Langer M, Cigada M, Mandelli M, Mosconi P, Tognoni G. Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med. 1987; 13: 342-346. (Pubitemid 17112389)
42. Gastmeier P, Sohr D, Geffers C, Ruden H, Vonberg RP, Welte T. Early- and late-onset pneumonia: is this still a useful classification? Antimicrob Agents Chemother. 2009; 53: 2714-2718.
43. Wunderink RG. Clinical criteria in the diagnosis of ventilator-associated pneumonia. Chest. 2000; 117 (4 Suppl 2): 191S-194S.
44. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000; 162: 505-511. (Pubitemid 30647191)
45. Fartoukh M, Maitre B, Honore S, Cerf C, Zahar JR, Brun-Buisson C. Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Am J Respir Crit Care Med. 2003; 168: 173-179. (Pubitemid 36920970)
46. Ramirez P, Garcia MA, Ferrer M, Aznar J, Valencia M, Sahuquillo JM et al. Sequential measurements of procalcitonin levels in diagnosing ventilator- associated pneumonia. Eur Respir J. 2008; 31: 356-362.
47. Michel F, Franceschini B, Berger P, Arnal JM, Gainnier M, Sainty JM et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest. 2005; 127: 589-597. (Pubitemid 40229322)
48. Luyt CE, Chastre J, Fagon JY.Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia. Intensive Care Med. 2004; 30: 844-852. (Pubitemid 38639476)
49. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator- associated pneumonia. N Engl J Med. 2006; 355: 2619-2630. (Pubitemid 44969121)
50. Torres A, El-Ebiary M. Bronchoscopic BALin the diagnosis of ventilator-associated pneumonia. Chest. 2000; 117 (4 Suppl 2): 198S-202S.
51. Cook D, Mandell L. Endotracheal aspiration in the diagnosis of ventilator-associated pneumonia. Chest. 2000; 117 (4 Suppl 2): 195S-197S. (Pubitemid 30230858)
52. Mauch H, Wagner J. MIQ - Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik. Heft 7: Infektionen der tiefen Atemwege, Teil 1. München: Urban & Fischer; 1999.
53. Gerbeaux P, Ledoray V, Boussuges A, Molenat F, Jean P, Sainty JM. Diagnosis of nosocomial pneumonia in mechanically ventilated patients: repeatability of the bronchoalveolar lavage. AmJ Respir Crit Care Med. 1998; 157: 76-80. (Pubitemid 28071264)
54. Llewelyn M, Cohen J. Diagnosis of infection in sepsis. Intensive Care Med. 2001; 27 (Suppl 1): S10-32.
55. Carratala J, Gudiol F, Pallares R, Dorca J, Verdaguer R, Ariza J et al. Risk factors for nosocomial Legionella pneumophila pneumonia. Am J Respir Crit Care Med. 1994; 149: 625-629. (Pubitemid 24082217)
56. Dobbins BM, Kite P, Wilcox MH. Diagnosis of central venous catheter related sepsis - a critical look inside. J Clin Pathol. 1999; 52: 165-172. (Pubitemid 29125406)
57. Sherertz RJ. Surveillance for infections associated with vascular catheters. Infect Control Hosp Epidemiol. 1996; 17: 746-752. (Pubitemid 126476393)
58. Blot F, Nitenberg G, Chachaty E, Raynard B, Germann N, Antoun S et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral- blood cultures. Lancet. 1999; 354: 1071-1077. (Pubitemid 29452819)
59. Tanguy M, Seguin P, Laviolle B, Desbordes L, Malledant Y. Hub qualitative blood culture is useful for diagnosis of catheter-related infections in critically ill patients. Intensive Care Med. 2005; 31: 645-648. (Pubitemid 40684981)
60. Catton JA, Dobbins BM, Kite P, Wood JM, Eastwood K, Sugden S et al. In situ diagnosis of intravascular catheter-related bloodstream infection: a comparison of quantitative culture, differential time to positivity, and endoluminal brushing. Crit Care Med. 2005; 33: 787-791.
61. Raad II, Baba M, Bodey GP. Diagnosis of catheter- related infections: the role of surveillance and targeted quantitative skin cultures. Clin Infect Dis. 1995; 20: 593-597.
62. Cobb DK, High KP, Sawyer RG, Sable CA, Adams RB, Lindley DA et al. A controlled trial of scheduled replacement of central venous and pulmonary- artery catheters. N Engl J Med. 1992; 327: 1062-1068.
63. Cook D, Randolph A, Kernerman P, Cupido C, King D, Soukup C et al. Central venous catheter replacement strategies: a systematic review of the literature. Crit Care Med. 1997; 25: 1417-1424. (Pubitemid 27347310)
64. Eyer S, Brummitt C, Crossley K, Siegel R, Cerra F. Catheter-related sepsis: prospective, randomized study of three methods of long-term catheter maintenance. Crit Care Med. 1990; 18: 1073-1079. (Pubitemid 20364044)
65. Brook I, Frazier EH. Aerobic and anaerobic microbiology of retroperitoneal abscesses. Clin Infect Dis. 1998; 26: 938-941. (Pubitemid 28180333)
66. Nichols RL, Smith JW. Wound and intraabdominal infections: microbiological considerations and approaches to treatment. Clin Infect Dis. 1993; 16 (Suppl 4): S266-272.
67. Brook I, Frazier EH. Microbiology of subphrenic abscesses: a 14-year experience. Am Surg. 1999; 65: 1049-1053. (Pubitemid 29517681)
68. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med. 2003; 31: 2228-2237. (Pubitemid 37011706)
69. Büchner T, Fegeler W, Bernhardt H, Brockmeyer N, Duswald KH, Herrmann M et al. Treatment of severe candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators. Eur J Clin Microbiol Infect Dis. 2002; 21: 337-352. (Pubitemid 34811966)
70. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001; 33: 177-186.
71. Petri MG, Konig J, Moecke HP, Gramm HJ, Barkow H, Kujath P et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med. 1997; 23: 317-325.
72. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004; 38: 161-189.
73. Richards M, Thursky K, Buising K. Epidemiology, prevalence, and sites of infections in intensive care units. Semin Respir Crit Care Med. 2003; 24: 3-22. (Pubitemid 36268567)
74. Wildemann B. Meningitis. Fortschr Neurol Psychiatr. 2005; 73: 102-117; quiz 118-119.
75. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004; 351: 1849-1859.
76. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004; 39: 1267-1284. (Pubitemid 39458512)
77. Diener HC, Ackermann H. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme; 2005.
78. Beckham JD, Tyler KL. Initial management of acute bacterial meningitis in adults: summary of IDSAguidelines. Rev Neurol Dis. 2006; 3: 57-60.
79. Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med. 2001; 345: 1727-1733.
80. Begg N, Cartwright KA, Cohen J, Kaczmarski EB, Innes JA, Leen CL et al. Consensus statement on diagnosis, investigation, treatment and prevention of acute bacterial meningitis in immunocompetent adults. British Infection Society Working Party. J Infect. 1999; 39: 1-15. (Pubitemid 29396599)
81. Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med. 1998; 129: 862-869. (Pubitemid 28549813)
82. Dunbar SA, Eason RA, Musher DM, Clarridge JE 3rd. Microscopic examination and broth culture of cerebrospinal fluid in diagnosis of meningitis. J Clin Microbiol. 1998; 36: 1617-1620. (Pubitemid 28226041)
83. Karandanis D, Shulman JA. Recent survey of infectious meningitis in adults: review of laboratory findings in bacterial, tuberculous, and aseptic meningitis. South Med J. 1976; 69: 449-457.
84. La Scolea LJ Jr, Dryja D. Quantitation of bacteria in cerebrospinal fluid and blood of children with meningitis and its diagnostic significance. J Clin Microbiol. 1984; 19: 187-190. (Pubitemid 14183575)
85. Poppert S, Essig A, Stoehr B, Steingruber A, Wirths B, Juretschko S et al. Rapid diagnosis of bacterial meningitis by real-time PCR and fluorescence in situ hybridization. J Clin Microbiol. 2005; 43: 3390-3397. (Pubitemid 40981352)
86. Tarafdar K, Rao S, Recco RA, Zaman MM. Lack of sensitivity of the latex agglutination test to detect bacterial antigen in the cerebrospinal fluid of patients with culture-negative meningitis. Clin Infect Dis. 2001; 33: 406-408. (Pubitemid 32664851)
87. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002; 347: 1549-1556.
88. van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis. 2004; 4: 139-143. (Pubitemid 38293137)
89. van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2007; CD004405.
90. Molyneux EM, Walsh AL, Forsyth H, Tembo M, Mwenechanya J, Kayira K et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet. 2002; 360: 211-218. (Pubitemid 34804649)
91. Scarborough M, Gordon SB, Whitty CJ, French N, Njalale Y, Chitani A et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa.N Engl J Med. 2007; 357: 2441-2450.
92. Joiner GA, Salisbury D, Bollin GE. Utilizing quality assurance as a tool for reducing the risk of ventilator- associated pneumonia. Am J Med Qual. 1996; 11: 100-103.
93. Zack J, Garrison T, Trovillion E, Clinkscale D, Coopersmith C, Fraser V et al. Effect of an education program aimed at reducing the occurence of ventilator-associated pneumonia. Crit Car Med. 2002; 30: 2407-2412. (Pubitemid 35351855)
94. Salahuddin N, Zafar A, Sukhyani L, Rahim S, Noor M, Hussain Ket al. Reducing ventilator-associated pneumonia rates through a staff education programme. J Hosp Infect. 2004; 57: 223-227. (Pubitemid 38967331)
95. Babcock HM, Zack JE, Garrison T, Trovillion E, Jones M, Fraser VJ et al. An educational intervention to reduce ventilator-associated pneumonia in an integrated health system: a comparison of effects. Chest. 2004; 125: 2224-2231. (Pubitemid 38788193)
96. Cocanour C, Peninger M, Domonoske B, Li T, Wright B, Valdivia A et al. Decreasing ventilator-associated pneumonia in a trauma ICU. J Trauma. 2006; 61: 122-129. (Pubitemid 44098329)
97. Jain M, Miller L, Belt D, King D, Berwick D. Decline in ICU adverse events, nosocomial infections and cost through a quality improvemnt initiative focusing on teamwork and culture change. Qual Saf Health Care. 2006; 15: 235-239.
98. Warren D, Zack J, Cox M, Cohen M, Fraser V. An educational intervention to prevent catheter-associated bloodstream infections in a non-teaching, community medical center. Crit Care Med. 2003; 31: 1959-1963. (Pubitemid 36900750)
99. Warren D, Zack J, Mayfield J, Chen A, Prentice D, Fraser V et al. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. Chest. 2004; 126: 1612-1618. (Pubitemid 39525038)
100. Berenholtz S, Pronovost P, Lipsett P, Hobson D, Earsing K, Farley J et al. Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med. 2004; 32: 2014-2020. (Pubitemid 39372534)
101. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006; 355: 2725-2732. (Pubitemid 46021509)
102. Stephan F, Sax H, Wachsmuth M, Hoffmeyer P, Clerque F, Pittet D. Reduction of urinary tract infection and antibiotic use after surgery: a controlled, prospective, before-after intervention study. Clin Infect Dis. 2006; 42: 1544-1551.
103. Anonymus. CDC definitions. www.cdc.gov/hcidod/dhqp/nhsn.html 2008.
104. Nationales Referenzzentrum für die Surveillance von nosokomialen Infektionen. http://www.nrzhygiene.de.
105. Gastmeier P, Geffers C, Brandt C, Zuschneid I, Sohr D, Schwab F et al. Effectiveness of a nationwide nosocomial infection surveillance system for reducing nosocomial infections. J Hosp Infect. 2006; 64: 16-22. (Pubitemid 44161382)
106. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002; 51: 1-45; quiz CE1-4.
107. Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneau S et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet. 2000; 356: 1307-1312.
108. Vernaz N, Sax H, Pittet D, Bonnabry P, Schrenzel J, Harbarth S. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother. 2008; 62: 601-607.
109. Raad II, Hohn DC, Gilbreath BJ, Suleiman N, Hill LA, Bruso PA et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol. 1994; 15: 231-238.
110. Parienti C, Lederle F, Impola C, Peterson L. Reduction of unnecessary intravenous catheter use: internal medicine house staff participate in a successful quality improvement project. Arch Intern Med. 1994; 154: 1829-1832. (Pubitemid 24261999)
111. Dezfulian C, Shojania K, Collard H, Kim H, Matthay M, Saint S. Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis. Am J Med. 2005; 118: 11-18. (Pubitemid 40082451)
112. Lorente L, Lecuona M, Jimenez A, Mora ML, Sierra A. Influence of an endotracheal tube with polyurethane cuff and subglottic secretion drainage on pneumonia. Am J Respir Crit Care Med. 2007; 176: 1079-1083. (Pubitemid 350223753)
113. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogue S, Ferrer M. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet. 1999; 354: 1851-1858.
114. Kollef MH. Ventilator-associated pneumonia. A multivariate analysis. JAMA. 1993; 270: 1965-1970.
115. Cook D, De Jonghe B, Brochard L, Brun-Buisson C. Influence of airway management on ventilator- associated pneumonia: evidence from randomized trials. JAMA. 1998; 279: 781-787. (Pubitemid 28115005)
116. Ibanez J, Penafiel A, Raurich JM, Marse P, Jorda R, Mata F. Gastroesophageal reflux in intubated patients receiving enteral nutrition: effect of supine and semirecumbent positions. JPEN J Parenter Enteral Nutr. 1992; 16: 419-422.
117. Iregui MG, Vaughan WM, Kollef MH. Non-pharmacological prevention of hospital-acquired pneumonia. Semin Respir Crit Care Med. 2002; 23: 489-496.
118. Orozco-Levi M, Torres A, Ferrer M, Piera C, el-Ebiary M, de la Bellacasa JP et al. Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. Am J Respir Crit Care Med. 1995; 152: 1387-1390.
119. Torres A, Serra-Batlles J, Ros E, Piera C, Puig de la Bellacasa J, Cobos A et al. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. Ann Intern Med. 1992; 116: 540-543.
120. Girou E, Buu-Hoi A, Stephan F, Novara A, Gutmann L, Safar M et al. Airway colonisation in long-term mechanically ventilated patients. Effect of semi-recumbent position and continuous subglottic suctioning. Intensive Care Med. 2004; 30: 225-233.
121. van Nieuwenhoven CA, Vandenbroucke-Grauls C, van Tiel FH, Joore HC, van Schijndel RJ, van der Tweel I et al. Feasibility and effects of the semirecumbent position to prevent ventilator-associated pneumonia: a randomized study. Crit Care Med. 2006; 34: 396-402. (Pubitemid 43145618)
122. Lewis S, Egger M, Sylvester P, Thomas S. Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and metaanalysis of controlled trails. BMJ. 2001; 323: 773-776.
123. Weimann A, Braga M, Harsanyi L, Laviano A, Ljungqvist O, Soeters P et al. ESPEN Guidelines on enteral nutrition: surgery including organ transplantation. Clin Nutr. 2006; 25: 224-244. (Pubitemid 43832525)
124. Heyland D, Novak F, Drover J, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA. 2001; 286: 944-953. (Pubitemid 33010341)
125. Heys S, Walker L, Smith I, Eremin O. Enteral nutritional supplementation with key nutritiens in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. Ann Surg. 1999; 229: 467-477. (Pubitemid 30191743)
126. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA. 2008; 300: 933-944.
127. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001; 345: 1359-1367.
128. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004; 79: 992-1000.
129. van den Berghe G et al. Intensive Insulin Therapy Study in Medical Intensive Care Patients. Amsterdam: ESICM; September 2005.
130. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360: 1283-1297.
131. Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009; 180: 821-827.
132. Brunkhorst FM, Wahl HG. Blood glucose measurements in the critically ill: more than just a blood draw. Crit Care. 2006; 10: 178.
133. Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004; 27: 553-591.
134. Nathens AB, Marshall JC. Selective decontamination of the digestive tract in surgical patients: a systematic review of the evidence. Arch Surg. 1999; 134: 170-176.
135. Silvestri L, van Saene HK, Milanese M, Gregori D, Gullo A. Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients. Systematic review of randomized, controlled trials. J Hosp Infect. 2007; 65: 187-203.
136. Krueger WA, Lenhart FP, Neeser G, Ruckdeschel G, Schreckhase H, Eissner HJ et al. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical trial.Am J Respir Crit Care Med. 2002; 166: 1029-1037. (Pubitemid 35178699)
137. Bergmans DC, Bonten MJ, Gaillard CA, Paling JC, van der Geest S, van Tiel FH et al. Prevention of ventilator-associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2001; 164: 382-388.
138. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med. 2009; 360: 20-31.
139. de Jonge E, Schultz M, Spanjaard L, Bossuyt P, Vroom M, Dan J et al. Effects of selective decontamination of digestive tract on mortality and acquistition of resistant bacteria in intensive care: a randomized controlled trial. Lancet. 2003; 362: 1011-1016. (Pubitemid 37186877)
140. de La Cal MA, Cerda E, Garcia-Hierro P, van Saene HK, Gomez-Santos D, Negro E et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo-controlled, double-blind trial. Ann Surg. 2005; 241: 424-430. (Pubitemid 40299718)
141. Heininger A, Meyer E, Schwab F, Marschal M, Unertl K, Krueger WA. Effects of long-term routine use of selective digestive decontamination on antimicrobial resistance. Intensive Care Med. 2006; 32: 1569-1576. (Pubitemid 44484347)
142. Leone M, Albanese J, Antonini F, Nguyen-Michel A, Martin C. Long-term (6-year) effect of selective digestive decontamination on antimicrobial resistance in intensive care, multiple-trauma patients. Crit Care Med. 2003; 31: 2090-2095. (Pubitemid 37011686)
143. Chlebicki MP, Safdar N. Topical chlorhexidine for prevention of ventilator-associated pneumonia: a meta-analysis. Crit Care Med. 2007; 35: 595-602. (Pubitemid 46148554)
144. Segers P, Speekenbrink RG, Ubbink DT, van Ogtrop ML, de Mol BA.
145. Kola A, Gastmeier P. Efficacy of oral chlorhexidine in preventing lower respiratory tract infections. Meta-analysis of randomized controlled trials. J Hosp Infect. 2007; 66: 207-216. (Pubitemid 46979844)
146. Chan EY, Ruest A, Meade MO, Cook DJ. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. BMJ. 2007; 334: 889.
147. Piarroux R, Grenouillet F, Balvay P et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med. 2004; 32: 2443-2449. (Pubitemid 39648226)
148. Ho K, Rochford S, John G. The use of topical non-absorabable gastrointestinal antifungal prophylaxis to prevent fungal infections in critically ill immunocompetent patients: a meta-analysis. Crit Care Med. 2005; 33: 2383-2392. (Pubitemid 41439740)
149. Veenstra D, Saint S, Saha S, Lumley T, Sullivan S. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection. JAMA. 1999; 281: 261-267. (Pubitemid 29058116)
150. Geffers C, Zuschneid I, Eckmanns T, Rüden H, Gastmeier P. The relationship between methodological trial quality and the effects of impregnated central venous catheters. Intensive Care Med. 2003; 29: 403-409. (Pubitemid 36379441)
151. Walder B, Pittet D, Tramèr M. Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis. Infect Control Hosp Epidemiol. 2002; 23: 748-756. (Pubitemid 36020213)
152. Johnson J, Kuskowski M, Wilt T. Systematic review: antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients. Ann Intern Med. 2006; 144: 116-126. (Pubitemid 46768230)
153. Falagas M, Fragoulis K, Bliziotis I, Chatzinikolaou I. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007; 59: 359-369. (Pubitemid 47073442)
154. Fridkin SK, Pear SM, Williamson TH, Galgiani JN, Jarvis WR. The role of understaffing in central venous catheter-associated bloodstream infection. Infect ControlHospEpidemiol. 1996; 17: 150-158. (Pubitemid 126469327)
155. Archibald LK, Manning ML, Bell LM, Banerjee S, Jarvis WR. Patient density, nurse-to-patient ratio and nosocomial infection risk in a pediatric cardiac intensive care unit. Pediatr Infect Dis. 1997; 16: 1045-1048. (Pubitemid 27494961)
156. Dorsey G, Borneo H, Sun S, Wells J, Steele L, Howland K et al. A heterogeneous outbreak of Enterobacter cloacae and Serratia marcescens infections in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2000; 21: 465-469. (Pubitemid 30620215)
157. Pessoa-Silva C, Toscano C, Moreira B, Santos A, Frota A, Solari C et al. Infection due to extended- spectrum beta-lactamase-producing Salmonella enterica subs. enterica serotype infantis in a neonatal unit. J Pediatr. 2002; 141: 381-387.
158. Robert J, Fridkin S, Blumberg H et al. The influence of the composition of the nursing staff on primary bloodstream infection rates in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2000; 21: 12-17.
159. Harbarth S, Sudre P, Dharan S, Cadenas M, Pittet D. Outbreak of Enterobacter cloacae related to understaffing, overcrowding, and poor hygiene practices. Infect Control Hosp Epidemiol. 1999; 20: 598-603.
160. Halwani M, Solaymani-Dodaran M, Grundmann H, Coupland C, Slack R. Cross-transmission of nosocomial pathogens in an adult intensive care unit: incidence and risk factors. J Hosp Infect. 2006; 63: 39-46.
161. Hugonnet S, Chevrolet JC, Pittet D. The effect of workload on infection risk in critically ill patients. Crit Care Med. 2007; 35: 76-81. (Pubitemid 46035680)
162. William BM, Thawani N, Sae-Tia S, Corazza GR. Hyposplenism: a comprehensive review. Part II: clinical manifestations, diagnosis, and management. Hematology. 2007; 12: 89-98.
163. Landgren O, Bjorkholm M, Konradsen HB, Soderqvist M, Nilsson B, Gustavsson A et al. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. J Intern Med. 2004; 255: 664-673. (Pubitemid 38703585)
164. Cherif H, Landgren O, Konradsen HB, Kalin M, Bjorkholm M. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine. 2006; 24: 75-81. (Pubitemid 41721102)
165. Davies JM, Barnes R, Milligan D. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med. 2002; 2: 440-443. (Pubitemid 35397712)
166. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003; 348: 1747-1755. (Pubitemid 36514705)
167. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodriguez T et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis. 2006; 43: 860-868. (Pubitemid 44435513)
168. Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middleaged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998; 351: 399-403.
169. Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg. 1999; 384: 24-32.
170. Barie PS, Williams MD, McCollam JS, Bates BM, Qualy RL, Lowry SF et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg. 2004; 188: 212-220. (Pubitemid 39278274)
171. Koperna T, Schulz F. Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection. World J Surg. 2000; 24: 32-37.
172. Kaiser RE, Cerra FB. Progressive necrotizing surgical infections - a unified approach. J Trauma. 1981; 21: 349-355.
173. Byrnes MC, Coopersmith CM. Prevention of catheter- related blood stream infection. Curr Opin Crit Care. 2007; 13: 411-415. (Pubitemid 47015777)
174. Zühlke H. Autologe Verfahren zur Therapie von Gefäß infektionen. Gefäßchirurgie. 2006; 11: 409-422.
175. Arens S, Hansis M. Implantate in der Unfallchirurgie - Osteosynthese mit Titan. Dtsch Ärzteblatt, Ärztliche Mitteilungen - Ausgabe A. 1998; 95: 1516-1518.
176. Sia IG, Berbari EF, Karchmer AW. Prosthetic joint infections. Infect Dis Clin North Am. 2005; 19: 885-914.
177. Mehendiratta V, McCarty BC, Gomez L, Graviss EA, Musher DM. Computerized tomography (CT)-guided aspiration of abscesses: outcome of therapy at a tertiary care hospital. J Infect. 2007; 54: 122-128. (Pubitemid 46075886)
178. Schneider JI. Rapid infectious killers. Emerg Med Clin North Am. 2004; 22: 1099-1115.
179. van Ruler O, Lamme B, Gouma DJ, Reitsma JB, Boermeester MA. Variables associated with positive findings at relaparotomy in patients with secondary peritonitis. Crit Care Med. 2007; 35: 468-476. (Pubitemid 46148537)
180. Pieracci FM, Barie PS. Intra-abdominal infections. Curr Opin Crit Care. 2007; 13: 440-449.
181. Klompas M, Yokoe DS. Automated surveillance of health care-associated infections. Clin Infect Dis. 2009; 48: 1268-1275.
182. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: a report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1999; 27: 279-284.
183. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007; 33: 606-618. (Pubitemid 46474888)
184. Freid MA, Vosti KL. The importance of underlying disease in patients with gram-negative bacteremia. Arch Intern Med. 1968; 121: 418-423.
185. McCabe WR, Jackson GG. Gram negative bacteremia. Arch Intern Med. 1962; 110: 92-100.
186. Bryant RE, Hood AF, Hood CE, Koenig MG. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med. 1971; 127: 120-128.
187. Young LS, Martin WJ, Meyer RD, Weinstein RJ, Anderson ET. Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med. 1977; 86: 456-471.
188. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980; 68: 344-355. (Pubitemid 10130374)
189. Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother. 1997; 41: 1127-1133. (Pubitemid 27194197)
190. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991; 115: 585-590.
191. Vidal F, Mensa J, Almela M, Martinez JA, Marco F, Casals C et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med. 1996; 156: 2121-2126.
192. Schiappa DA, Hayden MK, Matushek MG, Hashemi FN, Sullivan J, Smith KY et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis. 1996; 174: 529-536. (Pubitemid 26299686)
193. Caballero-Granado FJ, Cisneros JM, Luque R, Torres-Tortosa M, Gamboa F, Diez F et al. Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin. The Grupo Andaluz para el estudio de las Enfermedades Infecciosas. J Clin Microbiol. 1998; 36: 520-525.
194. Ispahani P, Pearson NJ, Greenwood D. An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. QJ Med. 1987; 63: 427-440. (Pubitemid 17084761)
195. Leibovici L, Drucker M, Konigsberger H, Samra Z, Harrari S, Ashkenazi S et al. Septic shock in bacteremic patients: risk factors, features and prognosis. Scand J Infect Dis. 1997; 29: 71-75.
196. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998; 244: 379-386. (Pubitemid 28513125)
197. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999; 115: 462-474. (Pubitemid 29083057)
198. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000; 118: 146-155. (Pubitemid 30485502)
199. Harbarth S, Ferriere K, Hugonnet S, Ricou B, Suter P, Pittet D. Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg. 2002; 137: 1353-1359; discussion 1359. (Pubitemid 35429592)
200. Hanon FX, Monnet DL, Sorensen TL, Molbak K, Pedersen G, Schonheyder H. Survival of patients with bacteraemia in relation to initial empirical antimicrobial treatment. Scand J Infect Dis. 2002; 34: 520-528.
201. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003; 115: 529-535. (Pubitemid 37352798)
202. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. The influence of inadequate empirical antimicrobial treatment in patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect. 2003; 9: 412-418. (Pubitemid 36758130)
203. Leone M, Bourgoin A, Cambon S, Dubuc M, Albanese J, Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med. 2003; 31: 462-467. (Pubitemid 36232941)
204. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003; 31: 2742-2751. (Pubitemid 38010630)
205. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004; 328: 668.
206. Heyland DK, Dodek P, Muscedere J, Day A, Cook D. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator- associated pneumonia. Crit Care Med. 2008; 36: 737-744.
207. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006; 355: 653-665.
208. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005; 41 (Suppl 5): S354-367.
209. Byl B, Jacobs F, Wallemacq P, Rossi C, de Francquen P, Cappello M et al. Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother. 2003; 47: 2015-2017. (Pubitemid 36637836)
210. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996; 38: 865-869. (Pubitemid 26413723)
211. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 2004; 30: 388-394. (Pubitemid 38375611)
212. Wunderink RG, Rello J, Cammarata SK, Croos- Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003; 124: 1789-1797. (Pubitemid 37433574)
213. Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005; 189: 425-428.
214. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005; 49: 2260-2266. (Pubitemid 40734452)
215. Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg. 2004; 188: 760-766.
216. Gang RK, Sanyal SC, Mokaddas E, Lari AR. Rifampicin as an adjunct to vancomycin therapy in MRSA septicaemia in burns. Burns. 1999; 25: 640-644. (Pubitemid 29440910)
217. Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F. In vitro activity of fosfomycin in combination with various anti-staphylococcal substances. J Antimicrob Chemother. 2001; 48: 209-217.
218. Yzerman EP, Boelens HA, Vogel M, Verbrugh HA. Efficacy and safety of teicoplanin plus rifampicin in the treatment of bacteraemic infections caused by Staphylococcus aureus. J Antimicrob Chemother. 1998; 42: 233-239. (Pubitemid 28393593)
219. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004; 38: 521-528.
220. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004; 170: 440-444. (Pubitemid 39214620)
221. Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snydman DR et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med. 1995; 155: 2429-2435.
222. Jacobs S, Price Evans DA, Tariq M, Al Omar NF. Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med. 2003; 31: 1938-1946. (Pubitemid 36900747)
223. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive Care Med. 2001; 27 (Suppl 1): S33-48.
224. Sobel JD, Rex JH. Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis. 2001; 33: 187-190.
225. Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, Kern WV et al. Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 2003; 82 (Suppl 2): S105-117.
226. Maschmeyer G, Böhme A, Buchheidt D, Cornely OA, Fricke H-J, Karthaus M, Lehrnbecher T, Link H, Shah PM, Wilhelm M. Diagnostik und Therapie von Infektionen bei Patienten in der Hämatologie und Onkologie. Leitlinien der Sektion Infektionen in der Hämatologie/Onkologie der Paul-Ehrlich- Gesellschaft e.V. Chemother J. 2004; 13: 134-141.
227. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001; 345: 1368-1377.
228. Swenson JD, Bull D, Stringham J. Subjective assessment of left ventricular preload using transesophageal echocardiography: corresponding pulmonary artery occlusion pressures. J Cardiothorac Vasc Anesth. 2001; 15: 580-583. (Pubitemid 32995816)
229. Buhre W, Buhre K, Kazmaier S, Sonntag H, Weyland A. Assessment of cardiac preload by indicator dilution and transoesophageal echocardiography. Eur J Anaesthesiol. 2001; 18: 662-667. (Pubitemid 32939482)
230. Kumar A, Anel R, Bunnell E, Habet K, Zanotti S, Marshall S et al. Pulmonary artery occlusion pressure and central venous pressure fail to predict ventricular filling volume, cardiac performance, or the response to volume infusion in normal subjects. Crit Care Med. 2004; 32: 691-699. (Pubitemid 38340065)
231. Godje O, Peyerl M, Seebauer T, Lamm P, Mair H, Reichart B. Central venous pressure, pulmonary capillary wedge pressure and intrathoracic blood volumes as preload indicators in cardiac surgery patients. Eur J Cardiothorac Surg. 1998; 13: 533-539; discussion 539-540.
232. Nguyen HB, Corbett SW, Steele R, Banta J, Clark RT, Hayes SR et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. Crit Care Med. 2007; 35: 1105-1112. (Pubitemid 46598962)
233. Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez- Diaz G, Garnacho-Montero J et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA. 2008; 299: 2294-2303. (Pubitemid 351724396)
234. Kortgen A, Niederprum P, Bauer M. Implementation of an evidence-based "standard operating procedure" and outcome in septic shock. Crit Care Med. 2006; 34: 943-949.
235. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008; 358: 125-139.
236. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet. 2001; 357: 911-916. (Pubitemid 32247279)
237. Zarychanski R, Turgeon A, Fergusson D, Cook D, Hébert P, Bagshaw S et al. Renal Outcomes Following Hydroxyethyl Strach Resuscitation: A Meta-Analysis Of Randomized Trials. Clinical & Investigative Medicine. 2008; 31 (Suppl 4): S26.
238. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev. 2010; CD007594.
239. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004; 350: 2247-2256. (Pubitemid 38669207)
240. Meier-Hellmann A. Hämodynamische Stabilisierung in der Sepsis. Anästhesiologie and Intensivmedizin. 2000; 41: 601-613.
241. 2 Collaborative Group. N Engl J Med. 1995; 333: 1025-1032.
242. Kern JW, Shoemaker WC. Meta-analysis of hemodynamic optimization in high-risk patients. Crit Care Med. 2002; 30: 1686-1692.
243. Hayes MA, Yau EH, Timmins AC, Hinds CJ, Watson D. Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption. Relationship to outcome. Chest. 1993; 103: 886-895.
244. Meier-Hellmann A, Bredle DL, Specht M, Hannemann L, Reinhart K. Dopexamine increases splanchnic blood flow but decreases gastric mucosal pH in severe septic patients treated with dobutamine. Crit Care Med. 1999; 27: 2166-2171. (Pubitemid 29508331)
245. Bennett ED. Dopexamine: much more than a vasoactive agent. Crit Care Med. 1998; 26: 1621-1622.
246. Byers RJ, Eddleston JM, Pearson RC, Bigley G, McMahon RF. Dopexamine reduces the incidence of acute inflammation in the gut mucosa after abdominal surgery in high-risk patients. Crit Care Med. 1999; 27: 1787-1793. (Pubitemid 29455105)
247. Kiefer P, Tugtekin I, Wiedeck H, Bracht H, Geldner G, Georgieff M et al. Effect of a dopexamine-induced increase in cardiac index on splanchnic hemodynamics in septic shock. Am J Respir Crit Care Med. 2000; 161: 775-779. (Pubitemid 30171730)
248. Schmidt W, Hacker A, Gebhard MM, Martin E, Schmidt H. Dopexamine attenuates endotoxin-induced microcirculatory changes in rat mesentery: role of beta2 adrenoceptors. Crit Care Med. 1998; 26: 1639-1645. (Pubitemid 28467670)
249. Mullner M, Urbanek B, Havel C, Losert H, Waechter F, Gamper G. Vasopressors for shock. Cochrane Database Syst Rev. 2004; CD003709.
250. Martin C, Viviand X, Leone M, Thirion X. Effect of norepinephrine on the outcome of septic shock. Crit Care Med. 2000; 28: 2758-2765.
251. Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007; 370: 676-684. (Pubitemid 47299251)
252. Prielipp RC, MacGregor DA, Royster RL, Kon ND, Hines MH, Butterworth JF. Dobutamine antagonizes epinephrine's biochemical and cardiotonic effects: results of an in vitro model using human lymphocytes and a clinical study in patients recovering from cardiac surgery. Anesthesiology. 1998; 89: 49-57.
253. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003; 107: 2313-2319. (Pubitemid 36578501)
254. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA 3rd. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med. 2001; 29: 487-493. (Pubitemid 32225288)
255. Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999; 47: 699-703; discussion 703-705.
256. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002; 96: 576-582. (Pubitemid 34193495)
257. Dunser MW, Mayr AJ, Tur A, Pajk W, Barbara F, Knotzer H et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med. 2003; 31: 1394-1398. (Pubitemid 36583849)
258. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008; 358: 877-887. (Pubitemid 351397087)
259. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000; 356: 2139-2143.
260. Marik PE, Iglesias J. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. NORASEPT II Study Investigators. Am J Med. 1999; 107: 387-390.
261. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. Am J Med. 1996; 101: 49-53.
262. Kellum JA, J MD. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001; 29: 1526-1531.
263. Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med. 2002; 28: 877-883.
264. Debaveye YA, Van den Berghe GH. Is there still a place for dopamine in the modern intensive care unit? Anesth Analg. 2004; 98: 461-468.
265. Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U et al. Acute renal failure in patients with severe sepsis and septic shock - a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant. 2008; 23: 904-909. (Pubitemid 351767542)
266. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11: R31.
267. Vinsonneau C, Camus C, Combes A, Costa de Beauregard MA, Klouche K, Boulain T et al. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet. 2006; 368: 379-385. (Pubitemid 44108121)
268. Kellum JA, Angus DC, Johnson JP, Leblanc M, Griffin M, Ramakrishnan N et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med. 2002; 28: 29-37. (Pubitemid 34118972)
269. Tonelli M, Manns B, Feller-Kopman D. Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis. 2002; 40: 875-885. (Pubitemid 35265466)
270. Augustine JJ, Sandy D, Seifert TH, Paganini EP. A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF. Am J Kidney Dis. 2004; 44: 1000-1007. (Pubitemid 39556479)
271. Gasparovic V, Filipovic-Grcic I, Merkler M, Pisl Z. Continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD) - what is the procedure of choice in critically ill patients? Ren Fail. 2003; 25: 855-862.
272. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A et al. Arandomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int. 2001; 60: 1154-1163. (Pubitemid 34207769)
273. Uehlinger DE, Jakob SM, Ferrari P, Eichelberger M, Huynh-Do U, Marti HP et al. Comparison of continuous and intermittent renal replacement therapy for acute renal failure. Nephrol Dial Transplant. 2005; 20: 1630-1637. (Pubitemid 41418587)
274. John S, Griesbach D, Baumgartel M, Weihprecht H, Schmieder RE, Geiger H. Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial. Nephrol Dial Transplant. 2001; 16: 320-327. (Pubitemid 32123921)
275. Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H et al. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis. 2004; 43: 342-349. (Pubitemid 38146333)
276. Schortgen F, Soubrier N, Delclaux C, Thuong M, Girou E, Brun-Buisson C et al. Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: usefulness of practice guidelines. Am J Respir Crit Care Med. 2000; 162: 197-202. (Pubitemid 30469820)
277. Misset B, Timsit JF, Chevret S, Renaud B, Tamion F, Carlet J. A randomized cross-over comparison of the hemodynamic response to intermittent hemodialysis and continuous hemofiltration in ICU patients with acute renal failure. Intensive Care Med. 1996; 22: 742-746. (Pubitemid 26355540)
278. Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H et al. The Hannover Dialysis Outcome Study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant. 2009; 24: 2179-2186.
279. Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009; 361: 1627-1638.
280. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008; 359: 7-20. (Pubitemid 351931092)
281. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med. 2002; 30: 2205-2211. (Pubitemid 35191568)
282. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000; 356: 26-30. (Pubitemid 30416991)
283. Saudan P, Niederberger M, De Seigneux S, Romand J, Pugin J, Perneger T et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int. 2006; 70: 1312-1317. (Pubitemid 44435183)
284. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002; 346: 305-310. (Pubitemid 34438837)
285. Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol. 2008; 19: 1233-1238.
286. DeVriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol. 1999; 10: 846-853. (Pubitemid 29149536)
287. van Deuren M, van der Meer JW. Hemofiltration in septic patients is not able to alter the plasma concentration of cytokines therapeutically. Intensive Care Med. 2000; 26: 1176-1178.
288. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med. 2009; 37: 803-810.
289. Hopkins RO, Weaver LK, Pope D, Orme JF, Bigler ED, Larson LV. Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999; 160: 50-56. (Pubitemid 29326067)
290. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000; 342: 1301-1308.
291. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998; 338: 347-354. (Pubitemid 28083906)
292. Villar J, Kacmarek RM, Perez-Mendez L, Aguirre-Jaime A. A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: a randomized, controlled trial. Crit Care Med. 2006; 34: 1311-1318.
293. Terragni PP, Rosboch G, Tealdi A, Corno E, Menaldo E, Davini O et al. Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2007; 175: 160-166. (Pubitemid 46115087)
294. Hager DN, Krishnan JA, Hayden DL, Brower RG. Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. Am J Respir Crit Care Med. 2005; 172: 1241-1245. (Pubitemid 43076561)
295. Bidani A, Tzouanakis AE, Cardenas VJ Jr, Zwischenberger JB. Permissive hypercapnia in acute respiratory failure. JAMA. 1994; 272: 957-962. (Pubitemid 24288551)
296. Hickling KG, Walsh J, Henderson S, Jackson R. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med. 1994; 22: 1568-1578. (Pubitemid 24320879)
297. Martin GS, Bernard GR. Airway and lung in sepsis. Intensive Care Med. 2001; 27 (Suppl 1): S63-S79.
298. Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V et al. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med. 2001; 345: 568-573. (Pubitemid 32772098)
299. Guerin C, Gaillard S, Lemasson S, Ayzac L, Girard R, Beuret P et al. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. JAMA. 2004; 292: 2379-2387. (Pubitemid 39491923)
300. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med. 1999; 25: 911-919.
301. Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K Jr et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004; 291: 1603-1609. (Pubitemid 38552433)
302. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a meta-analysis. Anesth Analg. 2003; 97: 989-998. (Pubitemid 37158678)
303. Esteban A, Alia I, Gordo F, Fernandez R, Solsona JF, Vallverdu I et al. Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. The Spanish Lung Failure Collaborative Group. Am J Respir Crit Care Med. 1997; 156: 459-465.
304. Esteban A, Alia I, Tobin MJ, Gil A, Gordo F, Vallverdu I et al. Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Spanish Lung Failure Collaborative Group. Am J Respir Crit Care Med. 1999; 159: 512-518.
305. Ely EW, Baker AM, Dunagan DP, Burke HL, Smith AC, Kelly PT et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med. 1996; 335: 1864-1869.
306. Ely EW, Bennett PA, Bowton DL, Murphy SM, Florance AM, Haponik EF. Large scale implementation of a respiratory therapist-driven protocol for ventilator weaning. Am J Respir Crit Care Med. 1999; 159: 439-446.
307. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987; 317: 653-658.
308. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987; 317: 659-665.
309. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008; 358: 111-124.
310. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med. 2003; 31: 141-145.
311. Zaloga GP, Marik P. Hypothalamic-pituitary-adrenal insufficiency. Crit Care Clin. 2001; 17: 25-41.
312. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid- binding globulin in human plasma. J Clin Endocrinol Metab. 1981; 53: 58-68. (Pubitemid 13245381)
313. Beishuizen A, Thijs LG, Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med. 2001; 27: 1584-1591. (Pubitemid 33027954)
314. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo- controlled, crossover study.AmJ Respir Crit Care Med. 2003; 167: 512-520.
315. Ali NA, O'Brien JM Jr, Dungan K, Phillips G, Marsh CB, Lemeshow S et al. Glucose variability and mortality in patients with sepsis. Crit Care Med. 2008; 36: 2316-2321.
316. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344: 699-709. (Pubitemid 32204987)
317. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005; 353: 1332-1341. (Pubitemid 41362701)
318. Vincent JL, Nadel S, Kutsogiannis DJ, Gibney RT, Yan SB,Wyss VL et al. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies. Crit Care. 2005; 9: R331-343.
319. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992; 116: 78-84.
320. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).AmJ Respir Crit Care Med. 2007; 176: 483-490.
321. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001; 286: 1869-1878.
322. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007; 35: 2677-2685. (Pubitemid 350175761)
323. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007; 35: 2686-2692. (Pubitemid 350175762)
324. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007; 35: 2693-2701. (Pubitemid 350175763)
325. Heyland DK. Selenium supplementation in critically ill patients: can too much of a good thing be a bad thing? Crit Care. 2007; 11: 153.
326. Forceville X, Laviolle B, Annane D, Vitoux D, BleichnerG, Korach JMet al. Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study. Crit Care. 2007; 11: R73.
327. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997; 336: 912-918.
328. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999; 341: 785-792. (Pubitemid 29420473)
329. Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Ann Surg. 1986; 203: 371-378.
330. Bone RC, Slotman G, Maunder R, Silverman H, Hyers TM, Kerstein MD et al. Randomized double- blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest. 1989; 96: 114-119.
331. Silverman HJ, Slotman G, Bone RC, Maunder R, Hyers TM, Kerstein MD et al. Effects of prostaglandin E1 on oxygen delivery and consumption in patients with the adult respiratory distress syndrome. Results from the prostaglandin E1 multicenter trial. The Prostaglandin E1 Study Group. Chest. 1990; 98: 405-410.
332. Abraham E, Baughman R, Fletcher E, Heard S, Lamberti J, Levy H et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med. 1999; 27: 1478-1485.
333. Yang S, Zhou M, Koo DJ, Chaudry IH, Wang P. Pentoxifylline prevents the transition from the hyperdynamic to hypodynamic response during sepsis. Am J Physiol. 1999; 277: H1036-1044.
334. Staubach KH, Schroder J, Stuber F, Gehrke K, Traumann E, Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg. 1998; 133: 94-100. (Pubitemid 28053174)
335. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo- controlled, double-blind trial. Crit Care Med. 1999; 27: 807-814. (Pubitemid 29218217)
336. Molnar Z, Shearer E, Lowe D. N-Acetylcysteine treatment to prevent the progression of multisystem organ failure: a prospective, randomized, placebo-controlled study. Crit Care Med. 1999; 27: 1100-1104. (Pubitemid 29314318)
337. Zhang P, Bagby GJ, Stoltz DA, Summer WR, Nelson S. Enhancement of peritoneal leukocyte function by granulocyte colony-stimulating factor in rats with abdominal sepsis. Crit Care Med. 1998; 26: 315-321. (Pubitemid 28082695)
338. Lundblad R, Nesland JM, Giercksky KE. Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Crit Care Med. 1996; 24: 820-826.
339. Karzai W, von Specht BU, Parent C, Haberstroh J, Wollersen K, Natanson C et al. G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med. 1999; 159: 1377-1382. (Pubitemid 29227841)
340. Heard SO, Fink MP, Gamelli RL, Solomkin JS, Joshi M, Trask AL et al. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The FilgrastimStudy Group. Crit Care Med. 1998; 26: 748-754.
341. Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S et al. Multicenter, double- blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med. 2003; 31: 367-373. (Pubitemid 36232927)
342. Pérez J, Dellinger RP. Other supportive therapies in sepsis. Intensive Care Med. 2001; 27 (Suppl 1): S116-127.
343. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med. 1982; 10: 448-450.
344. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J. 1981; 26: 115-117. (Pubitemid 11032070)
345. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341: 793-800.
346. Cestac P, Bagheri H, Lapeyre-Mestre M, Sie P, Fouladi A, Maupas E et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf. 2003; 26: 197-207. (Pubitemid 36308105)
347. Kreymann KG, Berger MM, Deutz NE, Hiesmayr M, Jolliet P, Kazandjiev G et al. ESPEN Guidelines on Enteral Nutrition: intensive care. Clin Nutr. 2006; 25: 210-223. (Pubitemid 43811686)
348. Sandstrom R, Drott C, Hyltander A, Arfvidsson B, Schersten T, Wickstrom I et al. The effect of postoperative intravenous feeding (TPN) on outcome following major surgery evaluated in a randomized study. Ann Surg. 1993; 217: 185-195. (Pubitemid 23059290)
349. Koretz RL, Avenell A, Lipman TO, Braunschweig CL, Milne AC. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol. 2007; 102: 412-429; quiz 468. (Pubitemid 46160556)
350. Peter JV, Moran JL, Phillips-Hughes J. A meta-analysis of treatment outcomes of early enteral versus early parenteral nutrition in hospitalized patients. Crit Care Med. 2005; 33: 213-220; discussion 260-261.
351. Barr J, Hecht M, Flavin KE, Khorana A, Gould MK. Outcomes in critically ill patients before and after the implementation of an evidence-based nutritional management protocol. Chest. 2004; 125: 1446-1457. (Pubitemid 38501362)
352. Petros S, Engelmann L. Enteral nutrition delivery and energy expenditure in medical intensive care patients. Clin Nutr. 2006; 25: 51-59. (Pubitemid 43263527)
353. Simpson F, Doig GS. Parenteral vs. enteral nutrition in the critically ill patient: a meta-analysis of trials using the intention to treat principle. Intensive Care Med. 2005; 31: 12-23. (Pubitemid 40174278)
354. Druml W, Fischer M, Ratheiser K. Use of intravenous lipids in critically ill patients with sepsis without and with hepatic failure. JPEN J Parenter Enteral Nutr. 1998; 22: 217-223.
355. Stoner HB, Little RA, Frayn KN, Elebute AE, Tresadern J, Gross E. The effect of sepsis on the oxidation of carbohydrate and fat. Br J Surg. 1983; 70: 32-35.
356. Battistella FD, Widergren JT, Anderson JT, Siepler JK, Weber JC, MacColl K. A prospective, randomized trial of intravenous fat emulsion administration in trauma victims requiring total parenteral nutrition. J Trauma. 1997; 43: 52-58; discussion 58-60.
357. Bertolini G, Iapichino G, Radrizzani D, Facchini R, Simini B, Bruzzone P et al. Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med. 2003; 29: 834-840. (Pubitemid 36609578)
358. Galban C, Montejo JC, Mesejo A, Marco P, Celaya S, Sanchez-Segura JM et al. An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients. Crit Care Med. 2000; 28: 643-648. (Pubitemid 30174256)
359. Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr. 2003; 27: 355-373. (Pubitemid 37022781)
360. Radrizzani D, Bertolini G, Facchini R, Simini B, Bruzzone P, Zanforlin G et al. Early enteral immunonutrition vs. parenteral nutrition in critically ill patients without severe sepsis: a randomized clinical trial. Intensive Care Med. 2006; 32: 1191-1198. (Pubitemid 44232414)
361. Pontes-Arruda A, Aragao AM, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006; 34: 2325-2333. (Pubitemid 44260016)
362. Gadek JE, DeMichele SJ, Karlstad MD, Pacht ER, Donahoe M, Albertson TE et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med. 1999; 27: 1409-1420.
363. Singer P, Theilla M, Fisher H, Gibstein L, Grozovski E, Cohen J. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med. 2006; 34: 1033-1038.
364. Bakalar B, Duska F, Pachl J, Fric M, Otahal M, Pazout J et al. Parenterally administered dipeptide alanyl-glutamine prevents worsening of insulin sensitivity in multiple-trauma patients. Crit Care Med. 2006; 34: 381-386. (Pubitemid 43145616)
365. Dechelotte P, Hasselmann M, Cynober L, Allaouchiche B, Coeffier M, Hecketsweiler B et al. L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study. Crit Care Med. 2006; 34: 598-604.
366. Goeters C, Wenn A, Mertes N, Wempe C, Van Aken H, Stehle P et al. Parenteral L-alanyl-L-glutamine improves 6-month outcome in critically ill patients. Crit Care Med. 2002; 30: 2032-2037.
367. Heyland DK, Dhaliwal R, Day AG, Muscedere J, Drover J, Suchner U et al. REducing Deaths due to OXidative Stress (The REDOXS Study): rationale and study design for a randomized trial of glutamine and antioxidant supplementation in critically- ill patients. Proc Nutr Soc. 2006; 65: 250-263. (Pubitemid 46323840)
368. Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996; 275: 308-314.
369. Basso N, Bagarani M, Materia A, Fiorani S, Lunardi P, Speranza V. Cimetidine and antacid prophylaxis of acute upper gastrointestinal bleeding in high risk patients. Controlled, randomized trial. Am J Surg. 1981; 141: 339-341. (Pubitemid 11113914)
370. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998; 338: 791-797. (Pubitemid 28135985)
371. Conrad SA, Gabrielli A, Margolis B, Quartin A, Hata JS, Frank WO et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med. 2005; 33: 760-765.
372. Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci. 1997; 42: 1255-1259. (Pubitemid 27343453)
373. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004; 171: 33-38. (Pubitemid 38925116)
374. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005; 294: 2989-2995. (Pubitemid 41817660)
375. Lau JY, Sung JJ, Lee KK, Yung MY, Wong SK, Wu JC et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000; 343: 310-316. (Pubitemid 30616696)
376. MacLaren R, Jarvis CL, Fish DN. Use of enteral nutrition for stress ulcer prophylaxis. Ann Pharmacother. 2001; 35: 1614-1623. (Pubitemid 34027465)
377. Cooper DJ, Walley KR, Wiggs BR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med. 1990; 112: 492-498.
378. Mathieu D, Neviere R, Billard V, Fleyfel M, Wattel F. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med. 1991; 19: 1352-1356.
379. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999; 340: 409-417.
380. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. J Am Med Association. 1993; 269: 3024-3029. (Pubitemid 23164346)
381. Lorente JA, Landin L, De Pablo R, Renes E, Rodriguez- Diaz R, Liste D. Effects of blood transfusion on oxygen transport variables in severe sepsis. Crit Care Med. 1993; 21: 1312-1318. (Pubitemid 23270500)
382. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007; 357: 965-976. (Pubitemid 47367076)
383. Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med. 2007; 176: 886-891. (Pubitemid 350097078)
384. Vorstand und Wissenschaftlicher Beirat der Bundesärztekammer. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Köln: Deutscher Ärzte-Verlag; 2003.
385. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008; 371: 126-134.
386. Brook AD, Ahrens TS, Schaiff R, Prentice D, Sherman G, Shannon W et al. Effect of a nursing- implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med. 1999; 27: 2609-2615. (Pubitemid 30027169)
387. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000; 342: 1471-1477.
388. Martin J, Bäsell K, Bürkle H, Hommel J, Huth G, Kessler P et al. Analgesie und Sedierung in der Intensivmedizin-Kurzversion. Anästhesiol Intensivmed. 2005; 1: S1-S20.
389. Payen JF, Bru O, Bosson JL, Lagrasta A, Novel E, Deschaux I et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. Crit Care Med. 2001; 29: 2258-2263. (Pubitemid 34038155)
390. Richman PS, Baram D, Varela M, Glass PS. Sedation during mechanical ventilation: a trial of benzodiazepine and opiate in combination. Crit Care Med. 2006; 34: 1395-1401.
391. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984; 310: 1415-1421. (Pubitemid 14101296)
392. den Brinker M, Joosten KF, Liem O, de Jong FH, Hop WC, Hazelzet JA et al. Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab. 2005; 90: 5110-5117. (Pubitemid 41262261)
393. Malerba G, Romano-Girard F, Cravoisy A, Dousset B, Nace L, Levy B et al. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med. 2005; 31: 388-392.
394. Ray DC, McKeown DW. Effect of induction agent on vasopressor and steroid use, and outcome in patients with septic shock. Crit Care. 2007; 11: R56.
395. Rossiter A, Souney PF, McGowan S, Carvajal P. Pancuronium-induced prolonged neuromuscular blockade. Crit Care Med. 1991; 19: 1583-1587.
396. Partridge BL, Abrams JH, Bazemore C, Rubin R. Prolonged neuromuscular blockade after long-term infusion of vecuronium bromide in the intensive care unit. Crit Care Med. 1990; 18: 1177-1179. (Pubitemid 20364064)
397. Vanderheyden BA, Reynolds HN, Gerold KB, Emanuele T. Prolonged paralysis after long-term vecuronium infusion. Crit Care Med. 1992; 20: 304-307.
398. Meyer KC, Prielipp RC, Grossman JE, Coursin DB. Prolonged weakness after infusion of atracurium in two intensive care unit patients. Anesth Analg. 1994; 78: 772-774. (Pubitemid 24112441)
399. Manthous CA, Chatila W. Prolonged weakness after the withdrawal of atracurium.AmJ Respir Crit Care Med. 1994; 150: 1441-1443.
400. Prielipp RC, Coursin DB, Scuderi PE, Bowton DL, Ford SR, Cardenas VJ Jr et al. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium51W89 in intensive care unit patients. Anesth Analg. 1995; 81: 3-12.
401. Lagneau F, D'Honneur G, Plaud B, Mantz J, Gillart T, Duvaldestin Pet al.A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients. Intensive Care Med. 2002; 28: 1735-1741.
402. Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA. Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life. Crit Care Med. 2000; 28: 3599-3605.
403. Korosec Jagodic H, Jagodic K, Podbregar M. Long-term outcome and quality of life of patients treated in surgical intensive care: a comparison between sepsis and trauma. Crit Care. 2006; 10: R134. (Pubitemid 47086959)
404. Granja C, Dias C, Costa-Pereira A, Sarmento A. Quality of life of survivors from severe sepsis and septic shock may be similar to that of others who survive critical illness. Crit Care. 2004; 8: R91-98.
405. Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry. 1984; 47: 1223-1231.
406. Tepper M, Rakic S, Haas JA, Woittiez AJ. Incidence and onset of critical illness polyneuropathy in patients with septic shock. Neth J Med. 2000; 56: 211-214. (Pubitemid 30255943)
407. Schelling G. Post-traumatic stress disorder in somatic disease: lessons from critically ill patients. Prog Brain Res. 2008; 167: 229-237. (Pubitemid 350123236)
408. Davydow DS, Gifford JM, Desai SV, Bienvenu OJ, Needham DM. Depression in general intensive care unit survivors: a systematic review. Intensive Care Med. 2009; 35: 796-809.
409. Graf J, Doig GS, Cook DJ, Vincent JL, Sibbald WJ. Randomized, controlled clinical trials in sepsis: has methodological quality improved over time? Crit Care Med. 2002; 30: 461-472.